Ahmadi T et al. Proc ASH 2011;Abstract 266.

Slides:

Advertisements

Similar presentations

Phase 1/2 Study of Weekly MLN9708, an Investigational Oral Proteasome Inhibitor, in Combination with Lenalidomide and Dexamethasone in Patients with Previously.

Advertisements

Efficacy and Safety of Three Bortezomib-Based Combinations in Elderly, Newly Diagnosed Multiple Myeloma Patients: Results from All Randomized Patients.

1Coiffier B et al. Proc ASH 2010;Abstract 114.

Palumbo A et al. Proc ASH 2012;Abstract 446.

Carfilzomib: High Single-Agent Response Rate with Minimal Neuropathy Even in High-Risk Patients 1 Baseline Peripheral Neuropathy Does Not Impact the Efficacy.

LaCasce A et al. Proc ASH 2014;Abstract 293.

Novel Agents for Indolent Lymphoma and Mantle Cell Lymphoma Stephen Ansell, MD, PhD Mayo Clinic.

Lesokhin AM et al. Proc ASH 2014;Abstract 291.

Results of a Phase II Trial of Brentuximab Vedotin as First Line Salvage Therapy in Relapsed/Refractory HL Prior to AHCT Chen RW et al. Proc ASH 2014;Abstract.

1 Baz R et al. Proc ASH 2014;Abstract Lacy MQ et al.

Efficacy of Denileukin Diftitox Retreatment in Patients with Cutaneous T-Cell Lymphoma Who Relapsed After Initial Response 1 Identification of an Active,

Single-Agent Lenalidomide in Patients with Relapsed/Refractory Mantle Cell Lymphoma Following Bortezomib: Efficacy, Safety and Pharmacokinetics from the.

Treatment with Bendamustine- Bortezomib-Dexamethasone in Relapsed/Refractory Multiple Myeloma Shows Significant Activity and Is Well Tolerated Ludwig H.

Interim Results of an International, Multicenter, Phase 2 Study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Relapsed or Refractory.

A Phase 2 Study of Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Updated.

R-CHOP vs R-FC Followed by Maintenance with Rituximab vs Interferon-Alfa in Elderly Patients with Mantle Cell Lymphoma Kluin-Nelemans HC et al. Proc ASH.

Viardot A et al. Proc ASH 2014;Abstract 4460.

Ibrutinib in Combination with Bendamustine and Rituximab Is Active and Tolerable in Patients with Relapsed/Refractory CLL/SLL: Final Results of a Phase.

A Phase II Study with Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) for Newly Diagnosed Multiple Myeloma Bringhen S et al. Proc ASH 2013;Abstract.

Ibrutinib, Single Agent or in Combination with Dexamethasone, in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Phase.

Dose-Adjusted EPOCH plus Rituximab in Untreated Patients with Poor Prognosis Large B-Cell Lymphoma, with Analysis of Germinal Center and Activated B-Cell.

Ruan J et al. Proc ASH 2013;Abstract 247.

Lenalidomide Is Safe and Active in Waldenstrom Macroglobulinemia (WM) 1 Updated Results from a Multicenter, Open-Label, Dose-Escalation Phase 1b/2 Study.

Rituximab Maintenance versus Wait and Watch After Four Courses of R-DHAP Followed by Autologous Stem Cell Transplantation in Previously Untreated Young.

A Phase 3 Study Evaluating the Efficacy and Safety of Lenalidomide Combined with Melphalan and Prednisone Followed by Continuous Lenalidomide Maintenance.

Rituximab plus Lenalidomide Improves the Complete Remission Rate in Comparison with Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in.

1 Flinn I et al. Proc ICML 2013;Abstract 084.

Maintenance Therapy with Bortezomib plus Thalidomide (VT) or Bortezomib plus Prednisone (VP) in Elderly Myeloma Patients Included in the GEM2005MAS65 Spanish.

ClaPD (Clarithromycin, Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma Mark TM et al. Proc ASH 2012;Abstract 77.

A Phase 3 Prospective, Randomized, International Study (MMY-3021) Comparing Subcutaneous and Intravenous Administration of Bortezomib in Patients with.

A Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car-Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma Shah.

An Open-Label, Randomized Study of Bendamustine and Rituximab (BR) Compared with Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab,

Ibrutinib in Combination with Rituximab (iR) Is Well Tolerated and Induces a High Rate of Durable Remissions in Patients with High- Risk Chronic Lymphocytic.

Moskowitz CH et al. Proc ASH 2014;Abstract 673.

Phase II Trial of R-CHOP plus Bortezomib Induction Therapy Followed by Bortezomib Maintenance for Previously Untreated Mantle Cell Lymphoma: SWOG 0601.

Phase II Multicenter Study of Single-Agent Lenalidomide in Subjects with Mantle Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib:

VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination with Bortezomib in Patients with Relapsed or Refractory.

Brentuximab Vedotin in Combination with RCHOP as Front-Line Therapy in Patients with DLBCL: Interim Results from a Phase 2 Study Yasenchak CA et al. Proc.

Results of a Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic HER2-Negative Breast.

MM-005: A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib,

Campos M et al. Proc EHA 2013;Abstract B2009.

Moskowitz CH et al. Proc ASH 2015;Abstract 182.

Campos M et al. Proc EHA 2013;Abstract B2009.

Palumbo A et al. Proc ASH 2012;Abstract 200.

Reeder CB et al. ASCO 2009; Abstract (Poster)

Attal M et al. Proc ASH 2010;Abstract 310.

Shustov AR et al. Proc ASH 2010;Abstract 961.

Nivolumab in Patients (Pts) with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL): Clinical Outcomes from Extended Follow-up of a Phase 1 Study.

Randomized, Open-Label Phase 1/2 Study of Pomalidomide Alone or in Combination with Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple.

Oki Y et al. Proc ASH 2013;Abstract 252.

Ibrutinib plus Rituximab in Treatment-Naive Patients with Follicular Lymphoma: Results from a Multicenter, Phase 2 Study1 Phase I Study of Rituximab,

Vahdat L et al. Proc SABCS 2012;Abstract P

Mateos MV et al. Proc ASH 2013;Abstract 403.

San Miguel JF et al. 1 Proc EHA 2013;Abstract S1151.

Kahl BS et al. Proc ASH 2011;Abstract LBA-6.

Dimopoulos MA et al. Proc ASH 2012;Abstract LBA-6.

Fowler NH et al. Proc ASCO 2010;Abstract 8036.

Ferrajoli A et al. Proc ASH 2010;Abstract 1395.

Jakubowiak AJ et al. Proc ASH 2010;Abstract 862.

Coiffier B et al. Proc ASH 2010;Abstract 857.

Ansell SM et al. Proc ASH 2012;Abstract 798.

Final Results of a Frontline Phase 1/2 Study of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (CRd) in Multiple Myeloma (MM)1 Final Results from.

Vitolo U et al. Proc ASH 2011;Abstract 777.

Forero-Torres A et al. Proc ASH 2011;Abstract 3711.

Zaja F et al. Proc ASH 2010;Abstract 966.

Pomalidomide plus Low-Dose Dexamethasone in Myeloma Refractory to Both Bortezomib and Lenalidomide: Comparison of Two Dosing Strategies in Dual-Refractory.

Advani RH et al. Proc ASH 2011;Abstract 443.

Boccadoro M et al. Proc ASCO 2011;Abstract 8020.

Coiffier B et al. Proc ASH 2011;Abstract 265.

Presentation transcript:

Ahmadi T et al. Proc ASH 2011;Abstract 266. Phase II Trial of Lenalidomide-Rituximab +/- Dexamethasone in Relapsed or Refractory Indolent B-Cell or Mantle Cell Lymphomas Resistant to Rituximab Ahmadi T et al. Proc ASH 2011;Abstract 266.

Background Single-agent rituximab has demonstrated activity in patients with relapsed low-grade or follicular lymphoma (JCO 1998;16:2825). However, approximately 50% of patients may not respond to initial rituximab treatment and most will become resistant to rituximab. Preclinical studies suggest that lenalidomide may act synergistically with rituximab to overcome clinical resistance to rituximab. Objective: Test the efficacy of lenalidomide combined with rituximab in patients with relapsed or refractory indolent B-cell or mantle-cell lymphoma (MCL). Ahmadi T et al. Proc ASH 2011;Abstract 266.

Trial Design Cohort 1 (n = 27) Cohort 2 (n = 21) Eligibility (n = 48) Relapsed/refractory indolent B-cell lymphoma or MCL Rituximab refractory: Lack of response or progression ≤6 months of standard course of rituximab monotherapy or rituximab-based regimen Cohort 1 (n = 27) Lenalidomide, 10 mg/d x 28 d, 2 cycles Dexamethasone, 8 mg/wk Cohort 2 (n = 21) Lenalidomide, 10 mg/d x 28 d, 2 cycles Part 1 Lenalidomide, 10 mg/d x 28 d Dexamethasone, 8 mg/wk Rituximab, 375 mg/m2 per wk x 4 Lenalidomide, 10 mg/d x 28 d Rituximab, 375 mg/m2 per wk x 4 Part 2* * Only patients with stable or responsive disease after Part 2 continued with treatment of lenalidomide +/- dexamethasone until disease progression. Response assessments were performed after Part 1 and after Part 2. Ahmadi T et al. Proc ASH 2011;Abstract 266.

Response Rates (Evaluable Patients, n = 40) Cohort 1 (n = 24) Cohort 2 (n = 16) Part 1 Part 2 Complete response (CR) 17% 33% 19% 50% Partial response (PR) 13% 25% Stable disease (SD) 63% 44% Progressive disease (PD) 8% 6% Overall response rate (ORR) 29% 58% 37% 75% For all evaluable patients (n = 40), ORR was 33% (Part 1) and 65% (Part 2). ORR by histology (after completion of Part 2): 67% (FL, n = 24); 60% (MCL, n = 10); 75% (SLL, n = 4); 50% (MZL, n = 50). Ahmadi T et al. Proc ASH 2011;Abstract 266.

Event-Free Survival (EFS) Intent to Treat Median EFS was 11.2 months n = 48 Percent survival Months With permission from Ahmadi T et al. Proc ASH 2011;Abstract 266.

Progression-Free Survival (PFS) from Last Dose of Rituximab Median PFS was 18.3 months n = 40 Percent survival Months With permission from Ahmadi T et al. Proc ASH 2011;Abstract 266.

Selected Adverse Events Event, n Cohort 1 (n = 27) Cohort 2 (n = 18) Fatigue 10 3 GI complaint 8 6 Tumor flare 5 Rash 4 Neutropenia 2 Neuropathy Anemia — Leukopenia Weight loss Periorbital edema Patients with dose interruptions: 14.8% (cohort 1); 50% (cohort 2), p = 0.02. Ahmadi T et al. Proc ASH 2011;Abstract 266.

Author Conclusions The combination of lenalidomide with low-dose dexamethasone and a 4-week course of rituximab produced a high ORR with durable responses (data not shown) in patients with rituximab-resistant small B-cell lymphoma. The response rate appears to improve following the addition of rituximab to lenalidomide-dexamethasone, although a delayed response to lenalidomide- dexamethasone is possible for some patients. It is possible that the “immunomodulatory” effects of lenalidomide may overcome resistance to rituximab in some patients. Ahmadi T et al. Proc ASH 2011;Abstract 266.

Investigator Commentary: Phase II Trial of Lenalidomide-Rituximab with or without Dexamethasone in B-Cell Lymphoma or MCL Lenalidomide has emerged as a promising drug for different types of non-Hodgkin lymphoma, including follicular lymphoma and MCL, especially in combination with rituximab. A registration-directed study is evaluating the potential approval of lenalidomide for patients with MCL. This study uses an interesting regimen. Presently, I use lenalidomide for patients, including a fair number of elderly patients, with relapsed or refractory MCL. Some have been receiving lenalidomide (10 mg/d, without breaks) for 1 to 2 or more years, and the drug is well tolerated. When administered at 25 mg/d for shorter periods, we find that lenalidomide is not as well tolerated in many of the elderly patients with MCL. Therefore, combinations such as lenalidomide with rituximab and dexamethasone may be particularly good for elderly patients with MCL who may not be great candidates for other combination therapies, let alone autologous stem cell transplant. Interview with Owen A O’Connor, MD, PhD, February 3, 2012